Financials in USD. Standardized financial statements.
A compact view of how TherapeuticsMD, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $3.02M | $1.76M | $1.30M | $69.96M | $2.57M | $64.87M | $49.65M | $16.10M | $16.78M | $19.36M |
| Revenue Growth? | +71.6% | +35.3% | -98.1% | +2619.1% | -96.0% | +30.7% | +208.4% | -4.0% | -13.3% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $1.40M | $1.40M | $15.97M | $6.33M | $2.74M | $2.64M | $4.19M |
| Gross Profit? | $3.02M | $1.76M | $1.30M | $68.57M | $1.17M | $48.90M | $43.31M | $13.36M | $14.14M | $15.17M |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +98.0% | +45.5% | +75.4% | +87.2% | +83.0% | +84.3% | +78.4% |
| Operating Expenses? | $7.24M | $6.52M | $9.82M | $67.38M | $80.75M | $204.44M | $194.52M | $143.58M | $91.77M | $105.42M |
| Operating Income? | -$4.21M | -$4.76M | -$8.52M | $1.19M | -$79.58M | -$155.54M | -$151.21M | -$130.22M | -$77.63M | -$90.25M |
| EBITDA? | -$3.02M | -$2.98M | -$8.08M | $11.86M | -$70.84M | -$153.41M | -$158.23M | -$127.65M | -$76.71M | -$89.74M |
| Income Before Tax | -$653,000 | -$2.34M | -$7.74M | $1.07M | -$79.31M | -$183.52M | -$176.15M | -$132.62M | -$76.93M | -$89.88M |
| Income Tax Expense | $0 | -$31,000 | -$43,000 | $0 | $0 | $0 | $0 | $0 | -$7,699 | $367,317 |
| Net Income? | -$569,000 | -$2.18M | -$10.28M | $112.00M | -$172.41M | -$183.52M | -$176.15M | -$132.62M | -$76.93M | -$89.88M |
| EPS? | $-0.05 | $-0.19 | $-0.55 | $-10.35 | $-25.83 | $-38.58 | $-39.79 | $-29.47 | $-18.71 | $-22.92 |
| Diluted EPS? | $-0.05 | $-0.19 | $-0.74 | $-10.35 | $-25.83 | $-38.58 | $-39.79 | $-29.47 | $-18.71 | $-22.92 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality